(CLOX) Series Portfolios Trust - Overview
Etf: CLOs, AAA-Rated, Non-Diversified, ETF
Dividends
| Dividend Yield | 5.18% |
| Yield on Cost 5y | 5.55% |
| Yield CAGR 5y | 34.15% |
| Payout Consistency | 94.7% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 1.59% |
| Relative Tail Risk | -5.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.21 |
| Alpha | 0.14 |
| Character TTM | |
|---|---|
| Beta | 0.081 |
| Beta Downside | 0.252 |
| Drawdowns 3y | |
|---|---|
| Max DD | 4.13% |
| CAGR/Max DD | 1.64 |
Description: CLOX Series Portfolios Trust January 02, 2026
The Series Portfolios Trust (NYSE ARCA:CLOX) is an actively managed, non-diversified ETF that allocates at least 80% of its net assets (plus any investment-purpose borrowings) to collateralized loan obligations (CLOs) that are AAA-rated or judged to be of equivalent quality at purchase.
Key metrics to watch: the fund’s weighted-average CLO duration (currently around 4.2 years) indicates moderate sensitivity to interest-rate moves; its 30-day SEC yield sits near 5.1%, reflecting the higher income profile of AAA-rated CLO tranches; and the portfolio’s concentration risk is high, with the top five holdings typically comprising over 40% of assets.
Sector drivers: CLO performance is closely tied to the health of the leveraged loan market, which in turn responds to corporate credit spreads, the pace of loan issuance, and macro-economic factors such as GDP growth and monetary policy. A tightening credit cycle or a sharp rise in default rates among underlying loans could pressure CLO tranche valuations, even for top-rated securities.
For a deeper, data-driven view of CLOX’s risk-adjusted return profile, you may find the analytics on ValueRay useful as a next step in your research.
What is the price of CLOX shares?
Over the past week, the price has changed by +0.11%, over one month by +0.47%, over three months by +1.37% and over the past year by +5.20%.
Is CLOX a buy, sell or hold?
What are the forecasts/targets for the CLOX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 28.1 | 10.1% |
CLOX Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 290.6m USD (290.6m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 290.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 290.6m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.21% (E(290.6m)/V(290.6m) * Re(6.21%) + (debt-free company))
Discount Rate = 6.21% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)